Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ARID1A mutation
i
Other names:
ARID1A, AT-Rich Interaction Domain 1A, SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator Of Chromatin Subfamily F Member 1, AT-Rich Interactive Domain-Containing Protein 1A, AT Rich Interactive Domain 1A (SWI-Like), ARID Domain-Containing Protein 1A, SWI/SNF Complex Protein P270, BRG1-Associated Factor 250a, SWI-Like Protein, Osa Homolog 1, SMARCF1, C1orf4, BAF250, HOSA1, OSA1, AT Rich Interactive Domain 1A (SWI- Like), Chromatin Remodeling Factor P250, BRG1-Associated Factor 250, OS
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
8289
Related biomarkers:
Mutation
CNA
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
ARID1A mutation
Non Small Cell Lung Cancer
ARID1A mutation
Non Small Cell Lung Cancer
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
ARID1A mutation
Non Small Cell Lung Cancer
ARID1A mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
ARID1A mutation
Renal Cell Carcinoma
ARID1A mutation
Renal Cell Carcinoma
sunitinib
Sensitive: B - Late Trials
sunitinib
Sensitive
:
B
sunitinib
Sensitive: B - Late Trials
sunitinib
Sensitive
:
B
ARID1A mutation
Ovarian Cancer
ARID1A mutation
Ovarian Cancer
NXP900
Sensitive: B - Late Trials
NXP900
Sensitive
:
B
NXP900
Sensitive: B - Late Trials
NXP900
Sensitive
:
B
ARID1A mutation
Ovarian Cancer
ARID1A mutation
Ovarian Cancer
NXP800
Sensitive: B - Late Trials
NXP800
Sensitive
:
B
NXP800
Sensitive: B - Late Trials
NXP800
Sensitive
:
B
ARID1A mutation
Endometrial Cancer
ARID1A mutation
Endometrial Cancer
DZR123
Sensitive: B - Late Trials
DZR123
Sensitive
:
B
DZR123
Sensitive: B - Late Trials
DZR123
Sensitive
:
B
ARID1A mutation
Ovarian Cancer
ARID1A mutation
Ovarian Cancer
DZR123
Sensitive: C2 – Inclusion Criteria
DZR123
Sensitive
:
C2
DZR123
Sensitive: C2 – Inclusion Criteria
DZR123
Sensitive
:
C2
ARID1A mutation
Hepatocellular Cancer
ARID1A mutation
Hepatocellular Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Cholangiocarcinoma
ARID1A mutation
Cholangiocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Gastric Cancer
ARID1A mutation
Gastric Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Esophageal Adenocarcinoma
ARID1A mutation
Esophageal Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Colorectal Cancer
ARID1A mutation
Colorectal Cancer
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
ARID1A mutation
Gastrointestinal Cancer
ARID1A mutation
Gastrointestinal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Head and Neck Cancer
ARID1A mutation
Head and Neck Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Breast Cancer
ARID1A mutation
Breast Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Bladder Cancer
ARID1A mutation
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Endometrial Adenocarcinoma
ARID1A mutation
Endometrial Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Pancreatic Ductal Adenocarcinoma
ARID1A mutation
Pancreatic Ductal Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Melanoma
ARID1A mutation
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Neuroendocrine Tumor
ARID1A mutation
Neuroendocrine Tumor
toripalimab-tpzi
Sensitive: C3 – Early Trials
toripalimab-tpzi
Sensitive
:
C3
toripalimab-tpzi
Sensitive: C3 – Early Trials
toripalimab-tpzi
Sensitive
:
C3
ARID1A mutation
Solid Tumor
ARID1A mutation
Solid Tumor
AZD6738
Sensitive: C3 – Early Trials
AZD6738
Sensitive
:
C3
AZD6738
Sensitive: C3 – Early Trials
AZD6738
Sensitive
:
C3
ARID1A mutation
Cervical Cancer
ARID1A mutation
Cervical Cancer
bevacizumab + rucaparib
Sensitive: C3 – Early Trials
bevacizumab + rucaparib
Sensitive
:
C3
bevacizumab + rucaparib
Sensitive: C3 – Early Trials
bevacizumab + rucaparib
Sensitive
:
C3
ARID1A mutation
Endometrial Cancer
ARID1A mutation
Endometrial Cancer
bevacizumab + rucaparib
Sensitive: C3 – Early Trials
bevacizumab + rucaparib
Sensitive
:
C3
bevacizumab + rucaparib
Sensitive: C3 – Early Trials
bevacizumab + rucaparib
Sensitive
:
C3
ARID1A mutation
Ovarian Cancer
ARID1A mutation
Ovarian Cancer
pembrolizumab + anlotinib
Sensitive: C3 – Early Trials
pembrolizumab + anlotinib
Sensitive
:
C3
pembrolizumab + anlotinib
Sensitive: C3 – Early Trials
pembrolizumab + anlotinib
Sensitive
:
C3
ARID1A mutation
Hepatocellular Cancer
ARID1A mutation
Hepatocellular Cancer
PD1 inhibitor + Angiogenesis inhibitor
Resistant: C3 – Early Trials
PD1 inhibitor + Angiogenesis inhibitor
Resistant
:
C3
PD1 inhibitor + Angiogenesis inhibitor
Resistant: C3 – Early Trials
PD1 inhibitor + Angiogenesis inhibitor
Resistant
:
C3
ARID1A mutation
Non Small Cell Lung Cancer
ARID1A mutation
Non Small Cell Lung Cancer
PD1 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor
Sensitive
:
C3
PD1 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor
Sensitive
:
C3
ARID1A mutation
Urothelial Cancer
ARID1A mutation
Urothelial Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Cholangiocarcinoma
ARID1A mutation
Cholangiocarcinoma
cisplatin + gemcitabine
Resistant: C3 – Early Trials
cisplatin + gemcitabine
Resistant
:
C3
cisplatin + gemcitabine
Resistant: C3 – Early Trials
cisplatin + gemcitabine
Resistant
:
C3
ARID1A mutation
Ovarian Cancer
ARID1A mutation
Ovarian Cancer
gemcitabine
Sensitive: C3 – Early Trials
gemcitabine
Sensitive
:
C3
gemcitabine
Sensitive: C3 – Early Trials
gemcitabine
Sensitive
:
C3
ARID1A mutation
Non-Hodgkin’s Lymphoma
ARID1A mutation
Non-Hodgkin’s Lymphoma
CAR-T immunotherapy
Resistant: C3 – Early Trials
CAR-T immunotherapy
Resistant
:
C3
CAR-T immunotherapy
Resistant: C3 – Early Trials
CAR-T immunotherapy
Resistant
:
C3
ARID1A mutation
Cholangiocarcinoma
ARID1A mutation
Cholangiocarcinoma
sintilimab
Sensitive: C4 – Case Studies
sintilimab
Sensitive
:
C4
sintilimab
Sensitive: C4 – Case Studies
sintilimab
Sensitive
:
C4
ARID1A mutation
Lymphoma
ARID1A mutation
Lymphoma
chidamide
Sensitive: C4 – Case Studies
chidamide
Sensitive
:
C4
chidamide
Sensitive: C4 – Case Studies
chidamide
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login